Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02140333
Recruitment Status : Unknown
Verified February 2015 by Jianxing He, The First Affiliated Hospital of Guangzhou Medical University. Recruitment status was: Recruiting
First Posted : May 16, 2014
Last Update Posted : February 12, 2015
The First Affiliated Hospital of Guangzhou Medical University
Information provided by (Responsible Party):
Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
The purpose of this study is to determine whether 100mg erlotinib had similar effect compared with 150mg erlotinib in NSCLC patients with EGFR mutation in China.
Condition or disease
In China it was confirmed that 150mg Erlotinib was effective in NSCLC patients wtih EGFR mutation, but reducing dose occurring in some patients because of the drug related side-effects. Thus, we sought to investigate that in Chinese patients with EGFR mutation whether low dose (100mg) Erlotinib had similar efficacy but lower toxcities compared with standad dose (150mg) Erlotinib.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histological diagnosis of NSCLC with phase IIIB or IV disease;